Merck KGaA - Pfizer Alliance  

Frankfurter Strasse 250
Darmstadt,  D-64293

  • Booth: 9

Alliance between Merck KGaA, Darmstadt, Germany, and Pfizer Inc., New York, US- IO is top priority for both companies. Benefiting from each other’s strengths & further explore the potential of avelumab, an investigational anti-PD-L1 antibody first discovered & developed by Merck KGaA, the alliance will jointly develop & commercialize avelumab, advance Pfizer’s PD-1 antibody focusing to develop high-priority internat. clin. programs to investigate avelumab as monotherapy & in combination regimens.